Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project

Morton, Lindsay M.; Sampson, Joshua N.; Cerhan, James R.; Turner, Jennifer; Vajdic, Claire M.; Wang, Sophia; Smedby, Karin E.; Sanjosé, Sílvia de; Monnereau, Alain; Benavente, Yolanda; Bracci, Paige M.; Chiu, Brian C.‐H.; Skibola, Christine F.; Zhang, Yawei; Mbulaiteye, Sam M.; Spriggs, Michael; Robinson, Dennis P.; Norman, Aaron D.; Kane, Eleanor; Spinelli, John J.; Kelly, Jennifer L.; Vecchia, Carlo La; Maso, Luigino Dal; Maynadié, Marc; Kadin, Marshall E.; Cocco, Pierluigi; Costantini, Adele Seniori; Clarke, Christina A.; Roman, Eve; Miligi, Lucia; Colt, Joanne S.; Berndt, Sonja I.; Mannetje, Andrea ’t; Roos, Anneclaire J. De; Kricker, Anne; Nieters, Alexandra; Franceschi, Silvia; Melbye, Mads; Boffetta, Paolo; Clavel, Jacqueline; Linet, Martha S.; Weisenburger, Dennis D.; Slager, Susan L.

doi:10.1093/jncimonographs/lgu005

Cited by 55 publications

(52 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…InterLymph was initiated in 2001 and presently includes 20 studies with 17,500 cases of non-Hodgkin lymphomas (NHLs) and 23,000 controls. [122] Despite the challenge of harmonizing data across the different studies, MPE research through InterLymph has demonstrated epidemiologic similarities and differences across NHL subtypes. For example, autoimmune diseases, hepatitis and alcohol are risk factors for T-cell NHLs, marginal zone lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, while genetic variants (identified by GWAS) are the only established risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma.…”

Section: Mpe Pooling Projectsmentioning

confidence: 99%

Proceedings of the second international molecular pathological epidemiology (MPE) meeting

Ogino

Campbell

Nishihara

et al. 2015

Cancer Causes Control

View full text Add to dashboard Cite

Disease classification system increasingly incorporates information on pathogenic mechanisms to predict clinical outcomes and response to therapy and intervention. Technological advancements to interrogate omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, metagenomics, interactomics, etc.) provide widely-open opportunities in population-based research. Molecular pathological epidemiology (MPE) represents integrative science of molecular pathology and epidemiology. This unified paradigm requires multidisciplinary collaboration between pathology, epidemiology, biostatistics, bioinformatics, and computational biology. Integration of these fields enables better understanding of etiologic heterogeneity, disease continuum, causal inference, and the impact of environment, diet, lifestyle, host factors (including genetics and immunity), and their interactions on disease evolution. Hence, the Second International MPE Meeting was held in Boston in December 2014, with aims to: (1) develop conceptual and practical frameworks; (2) cultivate and expand opportunities; (3) address challenges; and (4) initiate the effort of specifying guidelines for MPE. The meeting mainly consisted of presentations of method developments and recent data in various malignant neoplasms and tumors (breast, prostate, ovarian and colorectal cancers, renal cell carcinoma, lymphoma, and leukemia), followed by open discussion sessions on challenges and future plans. In particular, we recognized need for efforts to further develop statistical methodologies. This meeting provided an unprecedented opportunity for interdisciplinary collaboration, consistent with the purposes of the BD2K (Big Data to Knowledge), GAME-ON (Genetic Associations and Mechanisms in Oncology), and Precision Medicine Initiatives of the U.S.A. National Institute of Health. The MPE Meeting Series can help advance transdisciplinary population science, and optimize training and education systems for 21st century medicine and public health.

show abstract

Section: Mpe Pooling Projectsmentioning

confidence: 99%

Proceedings of the second international molecular pathological epidemiology (MPE) meeting

Ogino

Campbell

Nishihara

et al. 2015

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…For the lifetime prevalence of atopic disorders, controls were selected from the InterLymph Project [13]. Because lifetime prevalence of atopic diseases differs significantly between European and North American centers, the odds ratios were calculated for controls evaluated at 5 centers in the United States (Figure 1) [14].…”

Section: Methodsmentioning

confidence: 99%

Investigation of Atopy in Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders

Vonderheid¹

2017

CDOAJ

View full text Add to dashboard Cite

show abstract

“…17,18 Large-scale case-control studies from multiple continents under the International Lymphoma Epidemiology Consortium will provide additional data for future historians. 19 …”

Section: Aetiology Of Non-hodgkin Lymphoma: Immune Dysregulationmentioning

confidence: 99%

A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma

Lakhtakia

Burney

2015

Sultan Qaboos Univ Med J

View full text Add to dashboard Cite

Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project

Cited by 55 publications

References 78 publications

Proceedings of the second international molecular pathological epidemiology (MPE) meeting

Proceedings of the second international molecular pathological epidemiology (MPE) meeting

Investigation of Atopy in Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders

A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma

Contact Info

Product

Resources

About